Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, primarily chronic lymphocytic leukemia and non‑Hodgkin lymphoma, in adult patients and is administered under specialist supervision.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, adhering to EU manufacturing standards and providing full batch documentation to ensure product integrity across global markets through rigorous quality controls.

Leukeran is an alkylating chemotherapy agent used in the management of hematologic malignancies.

- Chronic lymphocytic leukemia: helps control disease progression and prolongs survival. - Non‑Hodgkin lymphoma: contributes to tumor reduction and remission in eligible patients. - Hairy cell leukemia: provides disease control in patients unsuitable for more intensive therapy.

Leukeran may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting. - Loss of appetite. - Fatigue. - Mild leukopenia. - Alopecia. - Diarrhea.

Serious or Rare Side Effects: - Severe bone‑marrow suppression leading to pancytopenia. - Opportunistic infections due to immunosuppression. - Secondary malignancies such as acute leukemia. - Pulmonary toxicity, including interstitial pneumonitis. - Severe allergic reactions (anaphylaxis). - Hepatic dysfunction with elevated transaminases.

Before initiating Leukeran, several safety measures should be observed.

- Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: obtain baseline and periodic liver enzyme tests. - Avoid use in severe bone‑marrow suppression: contraindicated in patients with existing pancytopenia. - Use effective contraception: potential teratogenic risk warrants reliable birth control. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Leukeran can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: may markedly increase myelosuppression. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Myelosuppressive antibiotics (e.g., linezolid): may exacerbate bone‑marrow toxicity. - Anticoagulants such as warfarin: increased bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may raise risk of gastrointestinal irritation. - Allopurinol: can potentiate chlorambucil toxicity.